All news

© Getty Images

Verici Dx receives boost with Thermo Fisher licensing deal

By Isabel Cameron

Verici Dx, a company developing advanced clinical diagnostics for organ transplant, has entered into a global licensing partnership with healthcare giant Thermo Fisher to develop an assay for pre-transplant kidney testing.

© Getty Images

Not-for-profit alliance advocates for life sciences collaboration

By Liza Laws

The Pistoia Alliance is a global, not-for-profit alliance that advocates for greater collaboration in life sciences R&D. It has just announced its four new strategic priorities made up of global pharma and tech representatives to deliver new project...

© Getty Images

IO Biotech enrolls 380 Patients in phase 3 advanced melanoma trial

By Isabel Cameron

IO Biotech, a clinical-stage biopharma company developing therapeutic cancer vaccines, has completed enrollment in its phase 3 trial for IO102-IO103, in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced melanoma....

© Getty Images

Angle launches PD-L1 test to support cancer therapy studies

By Isabel Cameron

Angle, a liquid biopsy company with circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, has launched its Portrait PD-L1 test for the evaluation of PD-L1 protein expression on CTCs.

© Getty Images

WuXi Biologics bioconjugates spinout plans $470 million IPO

By Liza Laws

The Chinese contract research, development and manufacturing organization (CRDMO) WuXi XDC has launched a bid to raise up to HK$3.7 billion (US$470.3 million) in an initial public offering (IPO) on the Hong Kong Stock Exchange.

© Getty Images

BioCina to manufacture pneumococcal vaccines in expanded partnership

By Jonathan Smith

The Australian biotech GPN Vaccines has expanded a partnership with compatriot contract development and manufacturing organization (CDMO) BioCina to scale up the manufacture of its lead candidate vaccine against pneumococcal diseases such as pneumonia,...

© Getty Images

Atara licenses T cell therapy to Pierre Fabre for up to $640 million

By Jonathan Smith

As it extends its cash runway, the cell therapy developer Atara Biotherapeutics has expanded a partnership with Pierre Fabre Laboratories to commercialize the off-the-shelf T-cell therapy tabelecleucel (tab-cel) for a rare form of blood cancer.

Sanofi invests $30m in MeiraGTx’s gene therapy pipeline

Sanofi invests $30m in MeiraGTx’s gene therapy pipeline

By Jonathan Smith

The London and New York-based gene therapy player MeiraGTx Holdings has received a $30 million investment from Sanofi in addition to potential strategic deals with the big pharma company down the road.

© Getty Images

Q&A: CRB on the future of life sciences industry

By Isabel Cameron

Peter Walters is a fellow of Advanced Therapies at CRB and has 20 years of experience specializing in pharmaceutical process and facility design. We spoke to him about CRB's latest life sciences report and best practices that must be adopted across...

© Getty Images

ADC licensing deals reached peak of $16.6 billion in 2022

By Isabel Cameron

The biopharmaceutical industry witnessed a 400% growth in total deal value of antibody-drug conjugate (ADC) licensing agreements from 2017-2022 and reached a peak of $16.6 billion in 2022, reveals data and analytics company GlobalData.

Follow us

Webinars